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  Evidence-based answer
Antidepressants and lamotrigine are 
effective. Atypical antipsychotics, lithium, 
and anticonvulsants also may help. 
 Antidepressants, including tricyclics 
and selective serotonin reuptake inhibitors 
(SSRIs), are useful adjuncts in short-term 
treatment of bipolar depression and have 
low rates of inducing mania (strength of 
recommendation [SOR]: A, 1 systematic 
review and randomized controlled trials 
[RCTs]). Lamotrigine is benefi cial for both 
acute treatment of bipolar depression and 
prevention of recurrent episodes (SOR: A, 
1 systematic review and 1 RCT). 
 Some atypical antipsychotics alone 
(SOR: B, 2 RCTs) or in combination with 
antidepressants (SOR: B, 1 multicenter 
RCT) effectively treat acute bipolar 
depression. Lithium and anticonvulsants 
such as valproate also may be useful (SOR: 
B, limited number of studies with small 
sample sizes).
Clinical commentary
Many options, but patience is key
Many treatments for bipolar depression 
are reasonably effective, but the literature 
has little to say about which to choose. For 
milder depression, starting a (or adding 
a second) mood stabilizer, especially 
lamotrigine, or using empirically validated 
psychotherapy (cognitive-behavioral or 
interpersonal) seems a good fi rst step. 
More marked depression may merit 
treatment with an antidepressant (or 
olanzapine or quetiapine), but the patient 
should take a mood stabilizer concurrently 
to reduce the risk of switching to mania.
 Patients with a history of severe 
mania, rapid cycling, or antidepressant-
induced switch may be understandably 
wary of antidepressant treatment. 
Because of the risks of suicide, mania, 
or mixed mood states in bipolar patients, 
prudent care must include prompt 
psychiatric referral if necessary. Most 
treatments work slowly, so patience on 
the part of physician, patient, and family 
is important.
Larry S. Goldman, MD
Northwestern University 
Feinberg School of Medicine, Chicago 
❚ Evidence summary
Depression is the most common phase of 
bipolar disorder. Until recently, no spe-
cifi c pharmacotherapies approved by the 
United States Food and Drug Adminis-
tration have been available to treat this 
form of depression. 
Antidepressants and lamotrigine 
produce results
A systematic review of 4 RCTs (662 
patients) found that antidepressants—
fl uoxetine, paroxetine, imipramine, 
tranylcypromine, and selegiline (l-depre-
nyl)—signifi cantly increased treatment 
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response for bipolar type I or II disease 
at 4 to 10 weeks. About 75% of patients 
received a concurrent mood stabilizer 
or an atypical antipsychotic (relative 
risk [RR]=1.86; 95% confi dence inter-
val [CI], 1.49-2.30; number needed to 
treat=4.2; 95% CI, 3.2-6.4).1 Although 
a few head-to-head comparisons sug-
gested that some SSRIs and monoamine 
oxidase inhibitors are more effective 
fi rst-line agents than tricyclics, the differ-
ences were not signifi cant.1 
One systematic review identifi ed a 
single RCT of 195 adults with type I bi-
polar disorder who were experiencing a 
major depressive episode.2 Lamotrigine 
(200 mg/day) signifi cantly improved 
patient scores on the Montgomery-As-
berg Depression Rating Scale (MADRS; 
P<.05) and increased the response to 
treatment (measured by mean change in 
scores on the Clinical Global Impression 
Scale; P<.05). Response rates were 51% 
(200 mg/day), 41% (50 mg/day), and 
26% (placebo; P<.05).
Olanzapine works best 
with an antidepressant
In a double-blind, 8-week RCT involving 
84 international sites, 833 adults with 
bipolar I depression (MADRS score of 
≥20) received olanzapine, an olanzapine-
fl uoxetine combination (OFC), or pla-
cebo.3 Although the trial had a low com-
pletion rate (38.5%) and no fl uoxetine 
monotherapy arm, the olanzapine and 
OFC groups showed improvement in 
depressive symptoms (defi ned as ≥50% 
improvement in the MADRS total score). 
The olanzapine response rate was 39% 
(P<.02; odds ratio [OR]=1.46; 95% CI, 
1.07-2.00); the OFC response rate was 
56.1% (P<.001; OR=2.92; 95% CI, 
1.23-3.26). The OFC group showed sta-
tistically greater improvement than the 
olanzapine group. 
A secondary analysis assessed health-
related quality of life based on the Medi-
cal Outcomes Study 36-item Short-Form 
Health Survey (SF-36) and Quality of 
Life in Depression Scale (QLDS).4 OFC-
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treated patients showed greater improve-
ments in general health perception, social 
functioning, vitality, and a number of 
other depression markers compared with 
both the olanzapine monotherapy and 
placebo groups. However, the SF-36 and 
QLDS were administered in only 7 of 13 
participating countries, possibly skew-
ing results because of variations between 
countries in sociocultural factors and 
quality-of-life issues that may also affect 
mental health.
Quetiapine alone also helps
Two 8-week, double-blind RCTs assessed 
the effi cacy of quetiapine in treating bi-
polar I or II depression. The fi rst studied 
542 outpatients with acute bipolar de-
pression, randomly assigned to quetiap-
ine, 300 mg/day; quetiapine, 600 mg/day; 
or placebo. Mean changes in MADRS 
total scores were the primary outcome 
measures.5 Quetiapine showed dose-de-
pendent improvement in MADRS total 
scores after the fi rst week (P<.001), with 
a moderate clinical effect size of 0.67 at 
300 mg/day and a large effect size of 0.81 
at 600 mg/day. 
In the second RCT, 509 patients were 
randomized to double-blind treatment 
with quetiapine (300 or 600 mg/day) 
or placebo and assessed weekly with 
the MADRS and Hamilton Depression 
Rating Scale (HDRS).6 Improvements in 
mean HDRS scores were greater with 
both quetiapine doses than with placebo 
(P<.001). Clinical effect sizes were mod-
erate at week 8 (0.61 at 300 mg/day and 
0.54 at 600 mg/day), although dose titra-
tion effects were not established. 
Antidepressants don’t enhance 
the effect of lithium or valproate
A recent RCT demonstrated no improve-
ment in bipolar depression using parox-
etine or bupropion in conjunction with 
mood stabilizers (primarily lithium or 
valproate) compared with mood stabiliz-
ers alone. However, the trial also showed 
no difference in treatment-emergent ma-
nia between groups.7
Recommendations
The American Psychiatric Association 
(APA) recommends lithium or lamotri-
gine as fi rst-line treatment for acute bi-
polar depression. Antidepressant mono-
therapy is not recommended.8 Interper-
sonal therapy, cognitive behavior therapy, 
and psychosocial interventions may be 
useful additions. 
Depressive episodes with psychotic 
features require adjunctive treatment 
with an antipsychotic or electroconvul-
sive therapy, especially in the presence of 
life-threatening inanition or suicidality. 
The APA supports maintenance
therapy using lithium and valproate, 
with lamotrigine, carbamazepine, or 
oxcarbazepine as alternatives. If effec-
tive, the medication generally should be
continued. ■
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